TP53 and neoplasm: The authors reached this conclusion after using CRISPR to remove mutant p53 in 16 cell lines from seven different cancer types and two colon-cancer-derived organoids, finding that it affected neither the proliferation and response to chemotherapeutic drugs of cells or organoids in culture, nor the growth and metastasis of tumor xenografts in mice [13].